EUVIMEDEUVIMED entdecken
Open Access

Busulfan and melphalan (Bu-Mel) versus carboplatin, etoposide, and melphalan (CEM) conditioning regimens for autologous haematopoietic stem cell transplant in children and young adults with high-risk neuroblastoma

Aditya Kumar Gupta iD, Jagdish Prasad Meena, Shivam Bansal, Sanjana Sarangarajan, Manisha Komal, M Jeeva Sankar

Cochrane Database of Systematic Reviews · 2025

DOI: 10.1002/14651858.cd015131 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cochrane Database of Systematic Reviews, 2025. Verfasst von Aditya Kumar Gupta und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics (Division of Pediatric Oncology), All India Institute of Medical Sciences, New Delhi, India. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Hematopoietic Stem Cell Transplantation, Neuroblastoma, Transplantation Conditioning. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To compare the efficacy and safety of busulfan and melphalan (Bu-Mel) conditioning chemotherapy with carboplatin, etoposide, and melphalan (CEM) conditioning chemotherapy for autologous haematopoietic stem cell transplantation in children and young adults (0 to 21 years of age) with high-risk neuroblastoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsHematopoietic Stem Cell TransplantationNeuroblastomaTransplantation ConditioningAdolescentChildChild, PreschoolHumansInfantYoung AdultBusulfanCarboplatinEtoposideMelphalanRandomized Controlled Trials as TopicTransplantation, AutologousReview Literature as Topic

Substanzen

BusulfanCarboplatinEtoposideMelphalan

Autor:innen und Institutionen

  • Department of Pediatrics (Division of Pediatric Oncology), All India Institute of Medical Sciences, New Delhi, India.
  • Pediatric Oncology, Children's Hospital at Westmead, Sydney, Australia.
  • Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India.
  • Newborn Health Knowledge Centre, WHO Collaborating Centre for Training and Research in Newborn Care, Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India.

ORCID-Profile: Aditya Kumar Gupta

Zitieren

APA

Gupta, A. K., Meena, J. P., Bansal, S., Sarangarajan, S., Komal, M., & Sankar, M. J. (2025). Busulfan and melphalan (Bu-Mel) versus carboplatin, etoposide, and melphalan (CEM) conditioning regimens for autologous haematopoietic stem cell transplant in children and young adults with high-risk neuroblastoma. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.cd015131

Vancouver

Gupta AK, Meena JP, Bansal S, Sarangarajan S, Komal M, Sankar MJ. Busulfan and melphalan (Bu-Mel) versus carboplatin, etoposide, and melphalan (CEM) conditioning regimens for autologous haematopoietic stem cell transplant in children and young adults with high-risk neuroblastoma. Cochrane Database of Systematic Reviews. 2025. doi:10.1002/14651858.cd015131

BibTeX
@article{Gupta2025,
  author = {Gupta, Aditya Kumar and Meena, Jagdish Prasad and Bansal, Shivam and Sarangarajan, Sanjana and Komal, Manisha and Sankar, M Jeeva},
  title = {Busulfan and melphalan (Bu-Mel) versus carboplatin, etoposide, and melphalan (CEM) conditioning regimens for autologous haematopoietic stem cell transplant in children and young adults with high-risk neuroblastoma},
  journal = {Cochrane Database of Systematic Reviews},
  year = {2025},
  doi = {10.1002/14651858.cd015131}
}
Kostenlos starten →